Galapagos receives EUREKA innovation label and OSEO funding
Galapagos NV announced that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO. Accordingly, the Paris-based Galapagos R&D center will receive interest free loans from OSEO worth €1.2 M over the next two years. Galapagos will use the loans to help fund the pre-clinical development of SARM candidate drug GLPG0492 for cachexia and the antibody alliance with MorphoSys.
The Galapagos-MorphoSys antibody alliance also has been awarded the innovation label (E! 5036 GALASYS) by EUREKA, a European network that enhances European competitiveness through international collaboration. With the EUREKA label, Galapagos received the no-interest loan from the French governmental organization OSEO to help fund its part of the alliance. The EUREKA label recognizes the partners' combined cutting-edge capabilities to generate novel antibody therapeutics, a rapidly growing market currently worth over €20 billion. Galapagos and MorphoSys are developing fully human antibodies, which are recognized as the next generation of therapeutic antibodies.
"This attractive financing that our Paris-based R&D center has received from OSEO will support two highly innovative programs which we otherwise would have had to finance internally," said Onno van de Stolpe, CEO of Galapagos. "Both of these programs are on-track, with the SARM candidate drug scheduled to enter the clinic early next year."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous